Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions: Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, Sunitinib Malate, Trebananib; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 12
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 9 more

Conditions: Type II Diabetes Mellitus
Interventions: Spice polyphenols; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 35 Years to 70 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: High Blood Pressure
Interventions: Aliskiren 150 mg, Placebo, HCTZ, Aliskiren 300 mg; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Intermittent Claudication
Interventions: Placebo, Sapropterin Dihydrochloride; Other · Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 17
States / cities: Scottsdale, Arizona • Sacramento, California • San Diego, California + 14 more

Conditions: Coronary Arteriosclerosis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Hypertension
Interventions: Low-level tragus stimulation, Sham stimulation; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Type 2 Diabetes Mellitus
Interventions: Erythritol-containing beverage; Dietary Supplement
Lead sponsor: Boston University; Other
Eligibility: 35 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: Endocalyx, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 64 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Smoking, Cardiovascular Disease Risk
Interventions: Resistance Training (RT), Nicotine Replacement Therapy (NRT); Other · Biological
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 35 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV
Interventions: Tenofovir/emtricitabine, Tenofovir/emtricitabine/efavirenz, Raltegravir; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chronic Kidney Disease
Interventions: Immediate release sodium nitrite, Isoquercetin, placebos; Drug · Dietary Supplement · Other
Lead sponsor: Tulane University; Other
Eligibility: 21 Years to 74 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Aging
Interventions: Time Restricted Feeding; Behavioral
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 55 Years to 79 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Ischemia and No Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Coronary Vasospasm, Endothelial Dysfunction, Microvascular Angina, Chest Pain With Normal Coronary Angiography
Interventions: Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2032
U.S. locations: 9
States / cities: Los Angeles, California • Stanford, California • New Haven, Connecticut + 5 more

Conditions: Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
Interventions: BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel, Carboplatin, Gemcitabine, Paclitaxel, Eribulin, BNT327 Optimized Dose, BNT327 Equivalent Q3W Dose; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 13
States / cities: Beverly Hills, California • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Endothelial Dysfunction
Interventions: Not listed
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aging, Postmenopause, Obesity
Interventions: Beetroot Juice, Exercise Training; Dietary Supplement · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Diabetes Mellitus
Interventions: Resveratrol, Placebo; Dietary Supplement
Lead sponsor: Boston University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pediatric Solid Tumor, Refractory Tumor, Recurrent Tumor, CNS Malignancies
Interventions: Ramucirumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Months to 21 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 21
States / cities: Birmingham, Alabama • Monrovia, California • Orange, California + 18 more

Conditions: Psoriasis
Interventions: Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Gastric Cancer, Adenocarcinoma
Interventions: ramucirumab, Placebo, Best Supportive Care (BSC); Biological · Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 14
States / cities: Bakersfield, California • La Jolla, California • Redlands, California + 11 more

Conditions: Obstructive Sleep Apnea
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 30 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Diego, California

Conditions: Fuchs Endothelial Corneal Dystrophy
Interventions: Ripasudil, Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 21
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 17 more

Conditions: Nicotine Dependence
Interventions: one time exposure to e-cig with nicotine, one time exposure to e-cig without nicotine, one time exposure to empty e-cig; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 45 Years
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Effect of Endothelin-1 Receptor Blockade on Circulating Endothelial Microparticles Levels in Patients With Pulmonary Hypertension

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Effects of a Spiced Meat Patty on Inflammation in Men With Type 2 Diabetes

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease

The Effect of Exercise on Stem Cell Mobilization and Heart Function in Patients Undergoing Cardiac Rehabilitation

Neuromodulation in Patients With Pulmonary Arterial Hypertension

Pilot Study of the Effects of Erythritol on Endothelial Function in Patients With Type 2 Diabetes Mellitus

Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes

Effect of Resistance Training on Tobacco-Related Cardiovascular Disease Risk

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial

The Effect of Time-restricted Feeding on Physiological Function in Middle-aged and Older Adults

The DISCOVER INOCA Prospective Multi-center Registry

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Endothelial Dysfunction As A Predictor Of Perioperative Outcome

Beetroot Supplementation in Women Enjoying Exercise Together

Effects of Resveratrol on Endothelial Function in Type 2 Diabetes Mellitus

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Potential Mechanism of Exercise Impairment in OSA

A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

E-cigarettes and Blood Vessel Function